Results 1 to 10 of about 2,265 (188)

Tezepelumab can Restore Normal Lung Function in Patients with Severe, Uncontrolled Asthma: Pooled Results from the PATHWAY and NAVIGATOR Studies [PDF]

Pulmonary Therapy
Introduction This post hoc analysis assessed the ability of tezepelumab treatment to restore normal lung function in patients with severe, uncontrolled asthma with abnormal lung function at baseline pooled from the PATHWAY and NAVIGATOR studies.
Ian D. Pavord, Christopher E. Brightling, Stephanie Korn, Nicole L. Martin, Sandhia S. Ponnarambil, Nestor A. Molfino, Jane R. Parnes, Christopher S. Ambrose   +7 more
doaj   +4 more sources

Key role of thymic stromal lymphopoietin as a molecular target for biologic treatment of severe asthma [PDF]

Frontiers in Allergy
Thymic stromal lymphopoietin (TSLP) is an alarmin mainly released by airway epithelial cells injured by many environmental noxious agents such as aeroallergens, respiratory viruses, bacteria, airborne pollutants and cigarette smoking.
Corrado Pelaia, James Melhorn, Giovanni Paoletti, Giovanni Paoletti, Remo Poto, Remo Poto, Angelantonio Maglio, Claudia Crimi, Alessandro Vatrella, Giorgio Walter Canonica, Giorgio Walter Canonica, Girolamo Pelaia   +11 more
doaj   +5 more sources

Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma [PDF]

Open Respiratory Archives, 2023
The excellent results for monoclonal antibodies in the treatment of severe uncontrolled asthma (SUCA) represent a milestone in current treatment of asthmatic disorders.
Vicente Plaza, Conxa Cañete, Christian Domingo, Carlos Martínez Rivera, Xavier Muñoz   +4 more
doaj   +3 more sources

Tezepelumab in near-fatal asthma requiring VV-ECMO [PDF]

Respiratory Medicine Case Reports
Phase III studies have demonstrated that the anti-TSLP biologic tezepelumab significantly reduces asthma exacerbations in severe asthma, regardless of endotype. However, evidence on its use in near-fatal asthma is lacking. Tezepelumab's ability to reduce
Elisa Bentivegna, Greta Insalata, Luca Paita, Alessia Catalisano, Chiara Allegrini, Giovanni Cianchi, Manuela Bonizzoli, Federico Lavorini, Gianna Camiciottoli   +8 more
doaj   +2 more sources

Sequential Use of Tezepelumab and Bronchoscopic Lung Volume Reduction With Endobronchial Valves in a Patient With Severe Asthma‐COPD Overlap and Heterogeneous Emphysema: A Case Report [PDF]

Respirology Case Reports
Asthma‐COPD overlap (ACO) carries greater symptom burden, frequent exacerbations and impaired quality of life compared with asthma or COPD alone. Evidence‐based advanced therapies are lacking, and management is typically extrapolated from existing ...
Jonas Herth, Daniel Franzen
doaj   +2 more sources

Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort [PDF]

ERJ Open Research
Background Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin, has demonstrated efficacy for severe asthma in clinical trials, but real-world evidence remains limited.
Jasmin Khateeb, Mordechai R. Kramer, Ophir Freund, Reem Mhameed, Eviatar Naamany, Aviv Kupershmidt, Gal Elkayam, Anna Breslavsky, Dror Rosengarten, Yaniv Dotan, Ori Wand, Amir Bar-Shai   +11 more
doaj   +2 more sources

The emerging role of anti-thymic stromal lymphopoietin monoclonal antibody (Tezepelumab) in comorbid and non-comorbid CRSwNP patients: a scoping review [PDF]

Brazilian Journal of Otorhinolaryngology
Objective: This systematic review aims to evaluate the effectiveness of Tezepelumab, a monoclonal antibody targeting the thymic stromal lymphopoietin, in patients affected by chronic rhinosinusitis with nasal polyposis, both with and without comorbid ...
Antonio Moffa, Eugenio de Corso, Domiziana Nardelli, Antonella Loperfido, Jacopo Galli, Peter Baptista, Manuele Casale   +6 more
doaj   +2 more sources

The Impact of Monoclonal Antibodies on Airway Smooth Muscle Contractility in Asthma: A Systematic Review [PDF]

Biomedicines, 2021
Airway hyperresponsiveness (AHR) represents a central pathophysiological hallmark of asthma, with airway smooth muscle (ASM) being the effector tissue implicated in the onset of AHR.
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Giuseppina Bertorelli, Beatrice Ludovica Ritondo, Paola Rogliani, Alfredo Chetta   +6 more
doaj   +3 more sources

Which Is the Best Biologic for Nasal Polyps: An Updated Network Meta‐Analysis [PDF]

Clinical and Translational Allergy
Background Direct comparative efficacy data for biologics in chronic rhinosinusitis with nasal polyps (CRSwNP) remain limited, particularly for novel agents like tezepelumab, underscoring the need to identify optimal therapies for precision management ...
Xi Xu, Jinting Lin, Minting Luo, Qingwu Wu   +3 more
doaj   +2 more sources

Tezepelumab treatment for allergic bronchopulmonary aspergillosis

Respirology Case Reports, 2023
An 82‐year‐old man had been diagnosed with asthma. He experienced repeated exacerbations requiring treatment with a systemic corticosteroid despite being treated with medications including high‐dose fluticasone furoate/umeclidinium/vilanterol ...
Hiroaki Ogata, Kachi Sha, Yasuaki Kotetsu, Aimi Enokizu‐Ogawa, Katsuyuki Katahira, Akiko Ishimatsu, Kazuhito Taguchi, Atsushi Moriwaki, Makoto Yoshida   +8 more
doaj   +3 more sources